Skip to main content
Publications
Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170
Edwards T, Norcross L, Fine J, Martin S, Coulouvrat C, Spears P, Herold CI, Ferrari G, Onwudiwe N. Side effects and impacts of extended adjuvant endocrine therapy: a qualitative study among women with HR+/HER2- breast cancer. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023 Jun; 41(Suppl 16):e12509. doi: 10.1200/JCO.2023.41.16_suppl.e12509
Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Dave V, Downey C, Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu F, Brown J, Sonpavde GP. Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II). Poster presented at the 2023 ASCO Genitourinary Cancers Symposium; February 16, 2023. San Francisco, CA. [abstract] J Clin Oncol. 2023 Feb 1; 41(Suppl 4). doi: 10.1200/JCO.2023.41.6_suppl.465
Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.
Law EH, Galve-Calvo E, Wockel A, Parikh R, Kurosky SK, Derrien Ansquer V, Frugier G, Davis KL, Esterberg E, Oikonomidou O. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Poster presented at the 2021 San Antonio Breast Cancer Symposium (SABCS); December 7, 2021. San Antonio, TX. [abstract] Cancer Res. 2022 Feb 15; 82(4_Suppl):OT2-19-04. doi: 10.1158/1538-7445.SABCS21-OT2-19-04
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andre F. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer from SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-15. doi: 10.1200/JCO.20.01139
Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.
Wyrwicz L, Elimova E, Blum SI, Xiao H, Davenport E, Wang J, Hunter S, Li M, Kondo K, Mohler M. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4066. doi: 10.1200/JCO.2021.39.15_suppl.4066
Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).
Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.
Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Lamont Dawson K. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey. Poster presented at the 2019 ASCO Annual Meeting; May 2019. [abstract] J Clin Oncol. 2019 May 26; 37(15_suppl):e18198. doi: 10.1200/JCO.2019.37.15_suppl.e18198
Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174
Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120
Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD. Understanding factors associated with uptake of BRCA genetic testing among Orthodox Jewish women using a mixed-methods approach. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 2017. San Antonio, TX. [abstract] Cancer Res. 2018 Feb; 78(4 Suppl).
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X. Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.
Telfort J, Trivedi MS, Yi HS, Colbeth H, Vanegas A, Vargas J, Sandoval R, Wood J, Dimond J, Finkelstein J, Kukafka R, Crew KD. Implementing decision support for breast cancer chemoprevention in primary care. J Clin Oncol. 2017 May;35(15 Suppl):e13038. doi: 10.1200/JCO.2017.35.15_suppl.e13038
Ali-Shaw T, Ueng WA, Trivedi MS, Yi H, David RR, Vanegas A, Vargas JM, Sandoval R, Wood J, Kukafka R, Crew KD. Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. [abstract] Cancer Res. 2017 Feb; 77(4_Suppl). doi: 10.1158/1538-7445.SABCS16-P5-10-01
Ueng W, McGuinness J, Infante K, Trivedi MS, Yi HS, David R, Vanegas A, Vargas J, Sandoval R, Kukafka R, Crew KD. Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women. Poster presented at the 107th Annual Meeting of the American Association for Cancer Research; April 2016. New Orleans, LA. [abstract] Cancer Res. 2016 Jul; 76(14_Suppl). doi: 10.1158/1538-7445.AM2016-1790